Drugs in Dev. Podiatry
Phase I
BioStem Begins Trial for BioREtain® in Diabetic Foot Ulcers
Details : BR-AC is a structural tissue allograft composed of the amnion layer of the placental membrane. It is being investigated for diabetic foot ulcers.
Brand Name : BR-AC
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
October 02, 2024
BioStem Receives IRB Approval to Study Vendaje® for Diabetic Foot Ulcers
Details : Vendaje is a structural tissue allograft composed of the amnion layer of the placental membrane. It is being investigated for diabetic foot ulcers.
Brand Name : Vendaje
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
August 21, 2024
Recce Receives $2M US Defense Grant for RECCE® 327 Gel
Details : The funding aims to accelerate the development of RECCE 327 Gel (R327) for acute treatment of burn wound infections and downstream bacterial complications such as sepsis in a military setting.
Brand Name : Recce 327
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 16, 2024
Recce Pharmaceuticals Expands RECCE® 327 Gel Trials for Skin Infections
Details : R327 (RECCE-327) is a fast-acting anti-infective effective against Gram-positive & negative bacteria. It is under development for the treatment of acute bacterial skin and skin structure infections.
Brand Name : Recce 327
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 25, 2024
Cynata Therapeutics Completes Enrollment in Phase 1 Trial of CYP-006TK for Foot Ulcers
Details : CYP-006TK is a topical wound dressing, cell and gene therapy drug candidate, which is currently being evaluated for the treatment of patients with diabetic foot ulcers.
Brand Name : CYP-006TK
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
April 09, 2024
Encouraging Initial Data from CYP-006TK Diabetic Foot Ulcer Clinical Trial
Details : CYP-006TK consists of allogenic mesenchymoangioblast-derived mesenchymal stem cells or Cymerus™ MSCs, seeded onto a heptylamine plasma polymer-coated silicone dressing for diabetic foot ulcers.
Brand Name : CYP-006TK
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
February 26, 2024
Cell Research Corporation (CRC) Announces Positive Results of Phase I Study for CorLiCyte®
Details : CorLiCyte® is a live mesenchymal stem cell therapy derived from human umbilical cord lining stem cells, with a proprietary optimised expression of cytokines, growth and cellular factors for the treatment of a number of serious health conditions.
Brand Name : CorLiCyte
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
September 16, 2022
LOOKING FOR A SUPPLIER?
Reset All
